RANCHO CUCAMONGA, Calif. , March 21, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on March 20, 2018 , the United States Court for the District of Massachusetts (the “District Court”) entered final judgment in favor of Amphastar in a lawsuit brought by
Reports Net Revenues of $60.4 Million for the Three Months Ended December 31, 2017 RANCHO CUCAMONGA, Calif. , March 12, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months and fiscal year ended December
RANCHO CUCAMONGA, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2017 ended December 31, 2017 , after the market closes on Monday, March 12, 2018 , and will hold a conference call to
RANCHO CUCAMONGA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that today the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") for Sodium Nitroprusside Injection 25mg/mL, 2mL single
RANCHO CUCAMONGA, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that today the U.S. Food and Drug Administration ("FDA") granted approval of two abbreviated new drug applications (ANDAs) for Medroxyprogesterone Acetate Injectable Suspension, USP,
RANCHO CUCAMONGA, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 10:30 a.m.
RANCHO CUCAMONGA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2017, ended September 30, 2017, after the market closes on Wednesday, November 8, 2017, and will hold a conference call
RANCHO CUCAMONGA, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application (ANDA) for Neostigmine Methylsulfate Injection, USP, 1mg/mL, 10mL, and
RANCHO CUCAMONGA, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on September 19, 2017, the U.S. Food and Drug Administration ("FDA") granted approval of the company's abbreviated new drug application ("ANDA") for Sodium Bicarbonate injection
